Table 3. Follow-up analyses in EAGLE cases with and without strong evidence of EBV miRNAs as measured by real-time quantitative PCR.
| Patient | EBV miRNAs?a | ISH RNA control | EBER expression in tumour | EBER expression in stroma | IHC positivity for BMRF1 | Copies of EBV DNA/100 000 cells |
|---|---|---|---|---|---|---|
| 1 | Yes | 1 | NCb | No | No | 0 |
| 2 | Yes | 2 | No | No | No | 0 |
| 3 | Yes | 0 | No | No | No | 0 |
| 4 | Yes | 0 | No | No | No | 0 |
| 5 | Yes | NDc | No | No | No | 17 |
| 6 | Yes | 3 | No | No | No | 0 |
| 7 | No | 1 | NCb | No | No | 0 |
| 8 | No | 1 | NCb | No | No | 0 |
| 9 | No | 3 | No | No | No | 0 |
| 10 | No | 3 | No | No | No | 0 |
| 11 | No | 1 | No | No | No | 0 |
| 12 | No | 0 | No | Yesd | No | 17 |
Abbreviations: EAGLE=Environment And Genetics in Lung cancer Etiology; EBV=Epstein–Barr virus; miRNA=microRNA; IHC=immunohistochemistry; ISH=in situ hybridisation.
a
Yes=cases with ⩾50% EBV miRNA positivity (at least 6 out of 12 amplifications with detectable EBV miRNA); no=cases with <10% EBV miRNA positivity (⩽1 out of 12 amplifications with detectable EBV miRNA).
b
NC=no cancer identified in tested specimen.
c
ND=tissue lost from slide during ISH, and hence no RNA preservation control available.
d
Positivity in lymphoid cells.